会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • ARF-P19, a novel regulator of the mammalian cell cycle
    • ARF-P19是哺乳动物细胞周期的新型调节剂
    • US06407062B1
    • 2002-06-18
    • US09480718
    • 2000-01-07
    • Charles J. SherrDawn QuelleMartine F. RousselFrederique ZindyJason D. Weber
    • Charles J. SherrDawn QuelleMartine F. RousselFrederique ZindyJason D. Weber
    • C07K1400
    • C07K14/4738A01K2217/05A01K2217/075A61K38/00A61K48/00C07K14/4703C07K2319/00
    • The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.
    • INK4A(MTS1,CDKN2)基因编码细胞周期蛋白D-依赖性激酶CDK4和CDK6的特异性抑制剂(InK4a-p16)。 InK4a-p16可以阻断这些激酶磷酸化视网膜母细胞瘤蛋白(pRb),从而阻止细胞周期的G1期退出。 涉及编码InK4a-p16,INK4A的基因的缺失和突变频繁发生在癌细胞中,意味着像pRb一样的INK4a-p16抑制了肿瘤的制备。 然而,完全不相关的蛋白质(ARF-p19)主要来自小鼠INK4A基因的替代阅读框架。 ARF-p19 cDNA(SEQ ID NO:1)在啮齿动物成纤维细胞中的表达诱导G1期和G2期停滞。 蛋白质编码序列的经济再利用在哺乳动物基因组中是没有先例的,INK4a-p16和ARF-p19的单位遗传可能反映了细胞周期控制中两种蛋白质的双重要求。
    • 6. 发明授权
    • Nucleotide sequence encoding human cyclin A
    • 编码人细胞周期蛋白A的核苷酸序列
    • US6103887A
    • 2000-08-15
    • US210889
    • 1998-12-15
    • Christian BrechotJian WangXavier ChenivesseBerthold HengleinFrederique Zindy
    • Christian BrechotJian WangXavier ChenivesseBerthold HengleinFrederique Zindy
    • A61K38/00C07K14/47C07K16/18C12N15/113C12N15/12C07H21/04C12N15/11C12N15/63
    • C12N15/113C07K14/4738C07K16/18A61K38/00C12N2310/3513
    • The invention is directed generally to a DNA sequence coding for human cyclin A and in particular to antibodies, or antisera including such antibodies, which bind to human cyclin A as encoded by the sequence of SEQ ID NO: 1 and which are useful in detecting cellular proliferation. The antibodies of the invention can be polyclonal or monoclonal, and are preferably generated by injection of purified human cyclin A into an animal host. The invention is particularly advantageous because it has been discovered that the gene encoding for human cyclin A is a site for integration of the hepatitis B virus associated with hepatocellular carcinoma, and by detecting human cyclin A through the use of the antibodies of the invention, one can detect and diagnose cell proliferation. Through the use of the present invention, cell proliferation and tumorigenesis can thus be detected at early stages, and such conditions can then be treated or inhibited by the use of anti-sense human cyclin A DNA.
    • 本发明一般涉及编码人类细胞周期蛋白A的DNA序列,特别是编码抗体或包含此类抗体的抗血清,其结合如SEQ ID NO:1的序列编码的人细胞周期蛋白A并且可用于检测细胞 增殖。 本发明的抗体可以是多克隆的或单克隆的,并且优选通过将纯化的人细胞周期蛋白A注射到动物宿主中来产生。 本发明是特别有利的,因为已经发现编码人细胞周期蛋白A的基因是与肝细胞癌相关的乙型肝炎病毒整合的位点,并且通过使用本发明的抗体检测人细胞周期蛋白A 可以检测和诊断细胞增殖。 通过使用本发明,因此可以在早期阶段检测细胞增殖和肿瘤发生,然后可以通过使用反义人细胞周期蛋白A DNA来治疗或抑制这些病症。